MétaCan
Menu
← Back to cohort
Record W4408686531 · doi:10.1136/bmjopen-2024-088231

<b>P</b> robiotics <b>i</b> nfluencing <b>r</b> esponse of <b>a</b> ntibodies over <b>t</b> ime in <b>s</b> eniors after <b>CO</b> VID-19 <b>v</b> accine (PIRATES-COV): a randomised controlled trial protocol

2025· article· en· W4408686531 on OpenAlexafffundabout
Jean‐Charles Pasquier, Mélanie Plourde, Sheela Ramanathan, Nils Chaillet, Guy Boivin, Isabelle Laforest‐Lapointe, Hugues Allard‐Chamard, Geneviève Baron, Jean‐François Beaulieu, Tamás Fülöp, Mélissa Généreux, Benoı̂t Mâsse, Julie Robitaille, Louis Valiquette, Sarah Bilodeau, Danielle Buch, Alain Piché

Bibliographic record

VenueBMJ Open · 2025
Typearticle
Languageen
FieldMedicine
TopicSARS-CoV-2 and COVID-19 Research
Canadian institutionsCentre Hospitalier Universitaire de SherbrookeUniversité de MontréalUniversité LavalCentre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-MontréalUniversité de SherbrookeCentre Hospitalier de l’Université de Montréal
FundersCanadian Institutes of Health Research
KeywordsMedicineVaccinationAntibodyInternal medicineHepatitis BRandomized controlled trialPediatricsImmunology

Abstract

fetched live from OpenAlex

Introduction The elderly are particularly vulnerable to morbidity and mortality from COVID-19, the disease caused by the SARS-CoV-2. Approximately 20% of the elderly showed no antibodies 3–5 months post-second dose of the COVID-19 vaccine. As probiotics have been shown to increase influenza-specific antibody levels post-influenza vaccination, we aim to reduce the percentage of participants without antibodies against the SARS-CoV-2 spike protein receptor-binding domain (anti-S1-RBD) at 6 months post-vaccination. Methods and analysis Our study design is a double-blind randomised controlled trial, using intention-to-treat analysis. Eligible participants are a purposive sample of 688 adults aged 65–89 years, in Quebec, Canada, not diagnosed with COVID-19 in the 3 months prior to recruitment and who wish to receive a government-recommended mRNA booster (Pfizer-BioNTech, Moderna) vaccine. The intervention consists of one capsule/day of a probiotic dietary supplement of Lacticaseibacillus rhamnosus and Lacticaseibacillus casei 6×10 9 CFU/capsule or a placebo, for 15 days pre-booster and post-booster vaccine. All participants provide dried blood spot samples at three timepoints (inclusion, 3 and 6 months post-vaccination) and a stool sample for microbiome analysis. A subgroup of 100 participants living near Sherbrooke, Quebec, is expected to volunteer for two onsite blood-test visits (at inclusion and 6 months post-vaccination). The primary outcome is the percentage of participants without anti-S1-RBD antibodies at 6 months post-vaccination. Secondary outcomes include longitudinal analysis of anti-S1-RBD and anti-N antibodies at three timepoints. In the subgroup, serum levels of neutralising antibodies will be determined at inclusion and 6 months post-vaccination. Probiotic and vaccine side effects are monitored. At the end of the study, we expect to identify the adjuvant effect of probiotic on vaccine-induced immune response. Ethics and dissemination The study was approved by Research Ethics Board of the Centre Intégré Universitaire de Santé et des Services Sociaux de l’Estrie- Centre Hospitalier Universitaire de Sherbrooke ( CIUSSS de l’Estrie-CHUS ) and the CHU de Québec-Université Laval # MP-31-2022- 4598 as well as Health Canada. All participants will provide informed consent. Results will be disseminated to the scientific community and to all networks related in this research. Trial registration number NCT05195151 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.037
Threshold uncertainty score0.124

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0150.013
Meta-epidemiology (narrow)0.0060.003
Meta-epidemiology (broad)0.0100.004
Bibliometrics0.0020.002
Science and technology studies0.0020.004
Scholarly communication0.0030.003
Open science0.0030.001
Research integrity0.0070.004
Insufficient payload (model declined to judge)0.0370.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.471
Teacher spread0.412 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueBMJ Open→Same topicSARS-CoV-2 and COVID-19 Research→French-language works237,207→